(BONEX) Bonesupport Holding - Ratings and Ratios
Injectable Bio-Ceramic, Bone Graft, Bone Void Filler
BONEX EPS (Earnings per Share)
BONEX Revenue
Description: BONEX Bonesupport Holding
Bonesupport Holding AB is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes. The companys product portfolio includes CERAMENT Bone Void Filler, CERAMENT G, and CERAMENT V, which are designed to remodel to host bone and, in some cases, elute antibiotics to prevent and treat bone infections.
The companys products are used in various orthopedic applications, including trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. With a strong presence in Europe, North America, and internationally, Bonesupport Holding AB has established itself as a player in the biotechnology industry. Key performance indicators (KPIs) to watch include revenue growth, gross margin expansion, and the successful development of preclinical product candidates.
From a financial perspective, Bonesupport Holding ABs market capitalization stands at approximately 19.5 billion SEK, with a return on equity (RoE) of 17.73%. The companys high P/E ratio of 161.20 suggests that investors have high expectations for future growth. To meet these expectations, Bonesupport Holding AB will need to continue to innovate and expand its product offerings, while also demonstrating strong commercial execution and operational efficiency.
Some key metrics to monitor include the companys sales growth trajectory, its ability to expand its product pipeline, and its progress in achieving regulatory approvals for new products. Additionally, investors should keep an eye on the competitive landscape and the companys ability to maintain its market share in the face of competition from other orthobiologics companies.
Additional Sources for BONEX Stock
BONEX Stock Overview
Market Cap in USD | 2,318m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Biotechnology |
IPO / Inception |
BONEX Stock Ratings
Growth Rating | 68.4 |
Fundamental | 77.9 |
Dividend Rating | 0.0 |
Rel. Strength | 34.5 |
Analysts | - |
Fair Price Momentum | 419.06 SEK |
Fair Price DCF | 65.86 SEK |
BONEX Dividends
Currently no dividends paidBONEX Growth Ratios
Growth Correlation 3m | 32.2% |
Growth Correlation 12m | -18.2% |
Growth Correlation 5y | 88.3% |
CAGR 5y | 50.15% |
CAGR/Max DD 5y | 0.86 |
Sharpe Ratio 12m | -0.09 |
Alpha | 7.54 |
Beta | 0.170 |
Volatility | 44.72% |
Current Volume | 155.8k |
Average Volume 20d | 159.8k |
Stop Loss | 329 (-3.2%) |
As of July 31, 2025, the stock is trading at SEK 340.00 with a total of 155,828 shares traded.
Over the past week, the price has changed by +8.49%, over one month by +21.43%, over three months by +13.71% and over the past year by +15.18%.
Yes, based on ValueRay´s Fundamental Analyses, Bonesupport Holding (ST:BONEX) is currently (July 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 77.86 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BONEX is around 419.06 SEK . This means that BONEX is currently undervalued and has a potential upside of +23.25% (Margin of Safety).
Bonesupport Holding has no consensus analysts rating.
According to our own proprietary Forecast Model, BONEX Bonesupport Holding will be worth about 458.3 in July 2026. The stock is currently trading at 340.00. This means that the stock has a potential upside of +34.79%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 421.2 | 23.9% |
Analysts Target Price | - | - |
ValueRay Target Price | 458.3 | 34.8% |